Therefore, the use of CXCR2 inhibitors in combination with CCR2 inhibitors is recommended to reduce the overall suppressive myeloid cell count, thus fostering a more robust anti-tumor immune response in PDAC. This evidence concerns the gene CCR2 and neoplasm.